Cytokine Release Syndrome Management Market Insights Highlight Segment Expansion And Market Leadership

The management of cytokine release syndrome (CRS) is an increasingly important focus within healthcare, particularly as advanced therapies like CAR-T expand their reach. Understanding the market dynamics, key players, emerging trends, and segmentation offers valuable insight into how this field is evolving and what the future holds.

Projected Growth and Market Size of the Cytokine Release Syndrome Management Market
The cytokine release syndrome management market is poised for impressive growth, expected to reach $32.35 billion by 2030. This reflects a compound annual growth rate (CAGR) of 6.3% over the coming years. Several factors are driving this expansion, including the broader adoption of cell therapies, advancements in immunomodulatory treatments, improvements in early diagnosis, more standardized treatment protocols, and increasing use of oncology therapies. Key trends shaping the market include a growing reliance on IL-6 inhibitors, the widening application of CRS management in CAR-T therapies, an emphasis on early intervention strategies, greater use of intensive care monitoring, and the development of more targeted immunomodulators.

The cytokine release syndrome management market size has grown strongly in recent years. It will grow from $23.76 billion in 2025 to $25.31 billion in 2026 at a compound annual growth rate (CAGR) of 6.5%. The growth in the historic period can be attributed to growth of car-t therapies, limited crs treatment options, reliance on corticosteroids, hospital-based management, high mortality risk.

Download a free sample of the cytokine release syndrome management market report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=24199&type=smp&utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Top Companies Leading the Cytokine Release Syndrome Management Industry
The market features a range of prominent pharmaceutical and biotech companies actively operating in CRS management. These include Pfizer Inc., Johnson & Johnson Private Limited, F. Hoffmann-La Roche Ltd., AbbVie Inc., Sanofi S.A., Bristol Myers Squibb Company, Novartis AG, GlaxoSmithKline plc, Amgen Inc., Gilead Sciences Inc., Regeneron Pharmaceuticals Inc., Genentech Inc., Incyte Corporation, Swedish Orphan Biovitrum AB, Biocon Limited, MacroGenics Inc., Legend Biotech Corporation, Bluebird Bio Inc., InflaRx N.V., and Humanigen Inc.

A significant development occurred in March 2024 when Merck & Co., Inc., a US-based biopharmaceutical giant, acquired Harpoon Therapeutics for $680 million. This strategic move aims to enhance Merck's oncology portfolio by incorporating Harpoon's T-cell engager technology and its lead candidate MK-6070, which is currently undergoing Phase 1/2 clinical trials targeting advanced cancers. Harpoon Therapeutics specializes in T-cell engagers and focuses on its TriTAC-XR platform designed to reduce cytokine release syndrome while improving treatment efficacy.

View the full cytokine release syndrome management market report:
https://www.thebusinessresearchcompany.com/report/cytokine-release-syndrome-management-global-market-report?utm_source=OpenPR&utm_medium=Paid&utm_campaign=Aug_PR

Innovations and Emerging Trends in Cytokine Release Syndrome Management
Research and development efforts are largely centered around creating novel therapies that modulate immune responses to minimize the risk and severity of cytokine storms without impairing the body's ability to combat infections or cancer. One promising approach involves host-directed small molecule drugs, which are low molecular weight compounds targeting immune signaling pathways to suppress excessive cytokine release.

For example, in April 2025, CytoAgents Inc., a biotechnology firm based in the US, announced the completion of the first dose-escalation cohort in its Phase 1b/2a clinical trial for CTO1681. This investigational host-directed small molecule drug is designed to prevent and treat CRS in patients receiving CAR T-cell therapy. The trial results so far indicate a strong safety profile without dose-limiting toxicities or compromising CAR T-cell effectiveness. The study uses a rolling six dose-escalation design to evaluate the safety, tolerability, and early efficacy of CTO1681, as well as to determine the recommended dose for Phase 2.

Breakdown of Segments in the Cytokine Release Syndrome Management Market
This market is segmented according to several critical categories:

1) Treatment Type: Includes monoclonal antibodies, corticosteroids, intravenous immunoglobulin (IVIG), targeted therapy, supportive care, and other treatment forms.
2) Indication: Covers CAR T-cell therapy, immune checkpoint inhibitors, hematopoietic stem cell transplantation (HSCT), autoimmune diseases, infections, and other indications.
3) Route of Administration: Classified into intravenous (IV), subcutaneous (SC), oral, intramuscular (IM), intrathecal, and other routes.
4) End Users: Comprises hospital pharmacies, retail pharmacies, online pharmacies, specialty clinics, research institutions, and others.

Further subdivisions include:
- Monoclonal Antibodies such as Tocilizumab, Siltuximab, Infliximab, and Rituximab
- Corticosteroids like Dexamethasone, Prednisone, Methylprednisolone, and Hydrocortisone
- IVIG types including Immunoglobulin G (IgG), Immunoglobulin A (IgA), Immunoglobulin M (IgM), and polyvalent immunoglobulins
- Targeted Therapies such as Janus Kinase (JAK) inhibitors, Interleukin-6 (IL-6) inhibitors, Tumor Necrosis Factor-alpha (TNF-a) inhibitors, and Bruton's Tyrosine Kinase (BTK) inhibitors
- Supportive Care encompassing antipyretics, analgesics, intravenous fluids and electrolyte solutions, oxygen therapy, and vasopressors
- Other treatments like plasmapheresis, antihistamines, leukapheresis, experimental therapies, and nutritional support

Together, these segments offer a detailed framework for understanding the diverse treatment options, indications, and delivery methods that make up the cytokine release syndrome management market.

What's new in our 2026 market reports:

• Market attractiveness scoring and analysis
• Total addressable market (TAM) analysis
• Company scoring matrix graphics and tables
• Excel dashboards
• Market hotspots infographics
• Key technologies and future trends
• Updated graphics and tables

Reach out to us:
The Business Research Company: https://www.thebusinessresearchcompany.com/,
Americas +1 310-496-7795,
Europe +44 7882 955267,
Asia & Others +44 7882 955267 & +91 8897263534,
Email us at info@tbrc.info.

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Learn More About The Business Research Company
With over 17500+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead.Our flagship product, the Global Market Model (GMM), is a premier market intelligence platform delivering comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.